{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:29:58Z","timestamp":1791041398313,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13730-018-0364-8","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T04:48:03Z","timestamp":1537764483000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Crohn\u2019s disease following rituximab treatment in a patient with refractory nephrotic syndrome"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-1620","authenticated-orcid":false,"given":"Keishi","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuji","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/adc.57.7.544","volume":"5","author":"O Koskimies","year":"1982","unstructured":"Koskimies O. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;5:544\u20138.","journal-title":"Arch Dis Child"},{"key":"364_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","volume":"8","author":"P Tarshish","year":"1997","unstructured":"Tarshish P. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769\u201376.","journal-title":"J Am Soc Nephrol"},{"key":"364_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJM198202253060803","volume":"306","author":"HP Weber","year":"1982","unstructured":"Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie, Weber HP, Olbing H, et al. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl Med. 1982;306:451\u20134.","journal-title":"N Engl Med"},{"key":"364_CR4","first-page":"9","volume":"237","author":"T Takei","year":"2011","unstructured":"Takei T, Sugiura H, Nitta K. Biological preparation rituximab. J Clin Exp Med. 2011;237:9.","journal-title":"J Clin Exp Med"},{"key":"364_CR5","unstructured":"Suzuki Group. The diagnostic criteria and guide to medical care of ulcerative colitis and Crohn\u2019s disease: research study about the refractory inflammatory intestinal disorder. Public welfare labor science research expenses subsidy Policy study business such as refractory disease 2015. 2015."},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"J Shalhoub","year":"1974","unstructured":"Shalhoub J. Pathogenesis of lipoid nephrosis:a disorder of T-cell function. Lancet. 1974;2:556\u201360.","journal-title":"Lancet"},{"key":"364_CR7","first-page":"2833","volume":"17","author":"K Okazaki","year":"2002","unstructured":"Okazaki K, Chiba T. Cytokine network abnormality of the inflammatory bowel disease. Bioclinica. 2002;17:2833.","journal-title":"Bioclinica"},{"key":"364_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","volume":"20","author":"K Nozu","year":"2005","unstructured":"Nozu K, Iijima K, Fujisawa M. Rituximab treatment for post-transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005;20:1660\u20133.","journal-title":"Pediatr Nephrol"},{"key":"364_CR9","first-page":"2","volume":"42","author":"K Iijima","year":"2014","unstructured":"Iijima K. Rituximab physician-led clinical trial for childhood refractory nephrotic syndrome. Jpn Pharmacol Ther. 2014;42:2.","journal-title":"Jpn Pharmacol Ther"},{"key":"364_CR10","first-page":"869","volume":"73","author":"M Takao","year":"2015","unstructured":"Takao M. Molecularly targeted therapy and progressive multifocal leukoencephalopathy. Jpn J Clin Med. 2015;73:869\u201376.","journal-title":"Jpn J Clin Med"},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243\u20136.","journal-title":"Pediatrics"},{"key":"364_CR12","first-page":"191","volume":"241","author":"W Tomohiro","year":"2012","unstructured":"Tomohiro W, Tsutomu C. Immunopathogenesis of Crohn\u2019s disease due to NOD2 mutations. J Clin Exp Med. 2012;241:191\u20135.","journal-title":"J Clin Exp Med"},{"key":"364_CR13","first-page":"216","volume":"3","author":"W Tomohiro","year":"2009","unstructured":"Tomohiro W. An automatic bacteriophage and Crohn\u2019s disease. IBD. 2009;3:216\u201321.","journal-title":"IBD"},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00467-004-1573-2","volume":"19","author":"R David","year":"2004","unstructured":"David R, Ovadia S, Yaakov JA, Robert W, Vivian B. Tumor necrosis factor-\u03b1 blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol. 2004;19:1281\u20134.","journal-title":"Pediatr Nephrol"},{"key":"364_CR15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.V93433","volume":"9","author":"ET McCarthy","year":"1998","unstructured":"McCarthy ET, Sharma R, Scharma M, Li JZ, Ge XL, Dileezpan KN. TNF\u03b1 increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"364_CR16","first-page":"296","volume":"3","author":"J Tabrez","year":"2011","unstructured":"Tabrez J, Suraksha A, Abbas AM, Raj KS, et al. Cytokine gene polymorphism in idiopathic nephrotic syndrome children. Ind J Clin Biochem. 2011;3:296\u2013302.","journal-title":"Ind J Clin Biochem"},{"key":"364_CR17","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1093\/ndt\/gfi180","volume":"20","author":"G Chin","year":"2005","unstructured":"Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant. 2005;20:2824\u20136.","journal-title":"Nephrol Dial Transplant"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-018-0364-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0364-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0364-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T13:10:40Z","timestamp":1662124240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-018-0364-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1007\/s13730-018-0364-8","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}